

DAFTAR PUSTAKA

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA A Cancer J. Clin.* 2021, 71, 209–249.
2. Amiri A, Pourhanifeh MH, Mirzaei HR, Nahand JS, Moghoofei M, Sahebhasagh R, et al. Exosomes and lung cancer: roles in pathophysiology, diagnosis and therapeutic applications. *Curr Med Chem.* (2021) 28 (2):308– 28. doi: 10.2174/0929867327666200204141952
3. Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. *Lung.* (2020) 198(6):897–907. doi: 10.1007/s00408-020-00407- 5
4. Kalinke, L.; Thakrar, R.; Janes, S.M. The promises and challenges of early non-small cell lung cancer detection: Patient perceptions, low-dose CT screening, bronchoscopy and biomarkers. *Mol. Oncol.* 2021, 15, 2544–2564.
5. Deng C, Zhang N, Wang Y, et al. High Systemic Immune-Inflammation Index Predicts Poor Prognosis in Advanced Lung Adenocarcinoma Patients Treated with EGFR-TKIs. *Medicine*; 98, (2019).
6. Islas-Vazquez L, Aguilar D, Galicia-Velasco M, et al. IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T- Lymphocyte Subpopulations in Patients Treated for Lung Adenocarcinoma. *Biology (Basel)* 2020; 9: 376.
7. Guo W, Cai S, Zhang F, et al. Systemic Immune- Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients with Surgically Resected Non-Small Cell Lung Cancer. *Thorac Cancer* 2019; 10: 761–768.
8. Xie QK, Chen P, Hu WM, Sun P, He WZ, Jiang C, et al. The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. *J Transl Med.* (2018) 16(1):273. doi: 10.1186/ s12967-018-1638-9
9. Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. *Sci Rep.* (2019) 9(1):3284. doi: 10.1038/s41598-019-39150-0
10. Murthy P, Zenati MS, Al Abbas AI, Rieser CJ, Bahary N, Lotze MT, et al. Prognostic value of the systemic immune-inflammation index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer. *Ann Surg Oncol.* (2020) 27(3):898–906. doi: 10.1245/s10434-019-08094-0
11. Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of Systemic immune-inflammation index in cancer: a meta-analysis. *J Cancer.* (2018) 9 (18):3295–302. doi: 10.7150/jca.25691
12. Jusuf A, Wibawanto A, Icksan AG, Syahrudin E, Juniarti, Endardjo S. Kanker paru bukan sel kecil: pedoman nasional untuk diagnosis dan penatalaksanaan di Indonesia. Perhimpunan Dokter Paru Indonesia. 2015.p.1-24
13. Clark S, Alsubait S. Non-Small Cell Lung Cancer. [Updated 2023 Jan 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562307/>
- Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. *Ann Intern Med.* 2019 Jan 22;85(1)
- a J, Foretova L, Dabek J, et al. Family history and lung cancer risk: a multicentre case-control study in Eastern and Central Europe and meta-analysis. *Cancer Causes Control* 2010;21:1091-104.



16. Landi MT, Chatterjee N, Yu K, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. *Am J Hum Genet* 2009;85:679-91
17. Burns DM. Primary prevention, smoking, and smoking cessation: implications for future trends in lung cancer prevention. *Cancer*. 2020 Dec 01;89(11 Suppl):2506-9.
18. Hoffmann I, Hoffmann D. The changing cigarette: chemical studies and bioassays. In: Boyle P, Gray N, Henningfield JE, et al. editors. *Tobacco: Science, policy and public health*. New York, NY: Oxford University Press, 2010:93-126.
19. Grosche B, Kreuzer M, Kreisheimer M, Schnelzer M, Tschense A. Lung cancer risk among German male uranium miners: a cohort study, 1946-1998. *Br J Cancer*. 2016 Nov 06;95(9):1280-7.
20. De Matteis S, Consonni D, Bertazzi PA. Exposure to occupational carcinogens and lung cancer risk. Evolution of epidemiological estimates of attributable fraction. *Acta Biomed* 2018;79 Suppl 1:34-42.
21. Krewski D, Lubin JH, Zielinski JM, et al. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. *Epidemiology* 2020;16:137-45.
22. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell* [Internet]. 2011;144(5):646-74.
23. Singh, N.; Baby, D.; Rajguru, J.P.; Patil, P.B.; Thakkannavar, S.S.; Pujari, V.B. Inflammation and cancer. *Ann. Afr. Med.* 2019, 18, 121-126.
24. Begum, R.; Mohammad, A.; Tabassum, R.M.; Shaeri, N. The Role of Introns for the Development of Inflammation-Mediated Cancer Cell. In *Inflammation in the 21st Century*; Vijay, K., Aguilera, S.A., Shamsadin, A.S., Eds.; IntechOpen: Rijeka, Croatia, 2021; p. 9.
25. Nakano-Narusawa, Y.; Yokohira, M.; Yamakawa, K.; Ye, J.; Tanimoto, M.; Wu, L.; Mukai, Y.; Imaida, K.; Matsuda, Y. Relationship between Lung Carcinogenesis and Chronic Inflammation. *Cancers* 2021, 13, 2910.
26. Altorki, N.K.; Markowitz, G.J.; Gao, D.; Port, J.L.; Saxena, A.; Stiles, B.; McGraw, T.; Mittal, V. The lung microenvironment: An important regulator of tumour growth and metastasis. *Nat. Rev. Cancer* 2019, 19, 9-31.
27. Rajasegaran T, How CW, Saud A. Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing. *Pharmaceuticals* 2023, 16, 451. <https://doi.org/10.3390/ph16030451>.
28. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res*. 2014;20(23):6212-22.
29. Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. *Tohoku J Exp Med*. 2015;236(4):297-304.
30. Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, et al. Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer. *Sci Rep*. 2019;9(1):1-9.
31. Vannitamby A, Seow HJ, Anderson G, et al. Tumour-associated neutrophils and epithelial PTEN can promote corticosteroid-insensitive MMP-9 expression in the chronically inflamed lung microenvironment. *Thorax* 2014;69:1140-3.
32. Gao M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, et al. miR-141-3p can reduce anoikis and promote metastasis by activating YAP1 signaling.



Nat Commun 2017;8: 310.

33. Kruger P, Saffarzadeh M, Weber AN, et al. Neutrophils: Between host defence, immune modulation, and tissue injury. *PLoS Pathog* 2015;11:e1004651.65.
34. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. *Nat Rev Cancer* 2016;16:431-46.
35. Lee, I.K.; Song, H.; Kim, H.; Kim, I.S.; Tran, N.L.; Kim, S.H.; Oh, S.J.; Lee, J.M. ROR α Regulates Cholesterol Metabolism of CD8(+) T Cells for Anticancer Immunity. *Cancers* 2020, 12, 1733.
36. Orakpoghenor O, Avazi DO, Markus T, Olaolu O. Lymphocytes : A Brief Review -. 2019
37. Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. *JClin Invest.* 2019;114:1691–3.
38. Gong L, Cai Y, Zhou X, Yang H. Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1. *Pathol Oncol Res* 2019;18:989–96
39. Cedrés S, Torrejon D, Martinez A, Martinez P, Navarro A, Zamora E, Mulet-Margalef N, Felip E. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. *Clin Transl Oncol.* 2012;14:864–869. doi: 10.1007/s12094-012-0872.
40. Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M. Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer. *World J Surg Oncol.* 2015;13:291. doi: 10.1186/s12957-015-0710-7.
41. Gibson AJW, Li H, D'Silva A, Elegbede AA, Tudor RA, Otsuka S, et al. Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study. *Lung Cancer.* 2019 Aug;134:141–6.
42. MacRosty CR, Rivera MP. Lung Cancer in Women. *Clinics in Chest Medicine.* 2020 Mar;41(1):53–65.
43. Lian J, Yue Y, Yu W, Zhang Y. Immunosenescence: a key player in cancer development. *J Hematol Oncol.* 2020 Dec;13(1):151.
44. Vargas TPA, Al-Humiqani A, Mata DGMM, Menjak IB. Immunotherapy for older patients with cancer. *Current Opinion in Supportive and Palliative Care.* 2023;17(1):37–46.
45. Chen H, Wang D, Zhong Q, Tao Y, Zhou Y, Shi Y. Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. *Cancer Immunology, Immunotherapy.* 2020;69:2413–24.
46. Shepshelovich D, Xu W, Lu L, Fares A, Yang P, Christiani D, et al. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. *Journal of Thoracic Oncology.* 2019 Sep;14(9):1594–607.
47. Suster DI, Mino-Kenudson M. Molecular pathology of primary non-small cell lung cancer. *Archives of medical research.* 2020;51(8):784–98.
48. Marino FZ, Bianco R, Accardo M, Ronchi A, Cozzolino I, Morgillo F, et al. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. *International journal of medical sciences.* 2019;16(7):981.
49. N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The Advances in Lung-Cancer Treatment on Population Mortality. *N Engl J Med* 2013 Aug 13;369(7):640–9.
50. Ayil H, Varghese J, John MC, Rajanikant GK, Wilson CM, Al-Yozbaki M, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology



- and advances in early diagnostics and therapeutics. *Genes & Diseases*. 2023 May;10(3):960–89.
51. Cuomo A, Pirozzi F, Attanasio U, Franco R, Elia F, De Rosa E, et al. Cancer risk in the heart failure population: epidemiology, mechanisms, and clinical implications. *Current Oncology Reports*. 2021;23:1–11.
 52. Supabphol S, Seubwai W, Wongkham S, Saengboonmee C. High glucose: an emerging association between diabetes mellitus and cancer progression. *J Mol Med*. 2021 Sep;99(9):1175–93.
 53. Patel B, Priefer R. Impact of chronic obstructive pulmonary disease, lung infection, and/or inhaled corticosteroids use on potential risk of lung cancer. *Life Sciences*. 2022;294:120374.
 54. Wang NF, Tang HM, Liu FL, Hong QY. Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer. *Chinese Medical Journal*. 2020 Apr 5;133(7):786–91.
 55. Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-Based lung cancer screening: A systematic review. *Lung Cancer*. 2020 Sep;147:154–86.
 56. al. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors. *Cancer*. 2020 May 15;126(10):2288–95.
 57. Wu L, Ke L, Zhang Z, Yu J, Meng X. Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. *Front Oncol*. 2020 Dec 18;10:602762.
 58. Padinharayil H, Varghese J, John MC, Rajanikant GK, Wilson CM, Al-Yozbaki M, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. *Genes & Diseases*. 2023 May;10(3):960–89.
 59. Yousefi M, Ghaffari P, Nosrati R, Dehghani S, Salmaninejad A, Abarghan YJ, et al. Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer. *Cell Oncol*. 2020 Feb;43(1):31–49.
 60. Kang J, Chang Y, Ahn J, Oh S, Koo D, Lee Y, et al. Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population: A cohort study. *Intl Journal of Cancer*. 2019 Dec 15;145(12):3267–75.
 61. Nøst TH, Alcala K, Urbarova I, Byrne KS, Guida F, Sandanger TM, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. *Eur J Epidemiol*. 2021 Aug;36(8):841–8.
 62. Seban RD, Mezquita L, Berenbaum A, Dercle L, Botticella A, Le Pechoux C, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. *European Journal of Nuclear Medicine and Molecular Imaging*. 2020;47:1147–57.
 63. Biswas T, Kang KH, Gawdi R, Bajor D, Machtay M, Jindal C, et al. Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). *IJERPH*. 2020 Oct 30;17(21):7995.
 64. Wang J, Liu Y, Mi X, Shao M, Liu L. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics. *Ann Palliat Med*. 2021;9(3):967–78.

